Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
FDA Approves VIZZ, First Eye Drop That Improves Near Vision and Promises Up to 10 Hours of Effect. Developed by LENZ Therapeutics, the Drug Could Mark the Beginning of the End of Glasses for Presbyopia.
Ocular medicine has just reached a historic milestone: the Food and Drug Administration (FDA), the regulatory agency of the United States, approved VIZZ, the first and only eye drop capable of correcting near vision in adults with presbyopia — a condition popularly known as “aging vision.”
The product, developed by LENZ Therapeutics, promises to transform the optical market by offering a practical and non-invasive alternative for the 128 million adults in the United States who suffer from this problem.
What Is VIZZ and How Does It Work
The major innovation of VIZZ lies in its formulation based on aceclidine, a selective miotic agent for the pupil. This component acts on the sphincter muscle of the iris, causing it to contract and reducing the diameter of the pupil to less than 2 mm — creating the so-called pinhole effect, which increases depth of focus and significantly improves near vision, without causing myopic deviation.
-
Scientists may have found an absurd clue about how life began on Earth: mineral nanoparticles might have used light, heat, and electricity to transform non-living matter into the first biological building blocks.
-
AI may be close to discovering new laws of physics, but scientists have found a frightening error: the technology reduces expensive simulations by more than 10 times and yet may overlook unprecedented clues hidden in the universe.
-
China has deployed snake-shaped robots to slide along power lines, where they have already inspected over 130 kilometers of cables using cameras and sensors to detect damaged wires, worn-out parts, and overheating.
-
Students create a Lego boat to collect plastic from beaches, focus on clean energy, and aim to combat marine pollution.
Unlike conventional treatments such as corrective lenses or surgeries, VIZZ offers a quick, safe, and temporary solution:
- Effect in just 30 minutes after application;
- Duration of up to 10 hours with a single daily dose;
- Use without interfering with distance vision;
- Simple application, similar to a common eye drop.
Price, Availability, and How to Obtain
According to a statement from LENZ Therapeutics, the commercialization of VIZZ in the United States will begin in the fourth quarter of 2025. Prior to that, samples will be distributed to eye care professionals in October.
The drug will be sold exclusively with a prescription and will be available in two formats:
- US$ 79 (approximately R$ 431) for 25 doses — duration of 1 month;
- US$ 198 (approximately R$ 1,081) for 75 doses — duration of 3 months.
On the official website, it is already possible to reserve the product with a medical prescription.
Clinical Results and Safety
The FDA approval was based on three clinical studies involving 466 participants, who used the eye drop for 42 days. The results indicated:
- Considerable improvement in near vision in all tested groups;
- Onset of effect in half an hour and maintenance for up to 10 hours;
- Mild and transient side effects, such as ocular irritation, temporary blurred vision, and headaches.
According to clinical researcher Marc Bloomenstein, from the Schwartz Laser Eye Care Center (Arizona), VIZZ could become the new standard of treatment for presbyopia:
“This approval represents a disruptive paradigm shift in treatment options for millions of people struggling with age-related near vision loss.”
Why This Approval Is Historic
Until now, those with presbyopia relied almost exclusively on multifocal glasses or special contact lenses. Surgeries such as LASIK for presbyopia are also options, but they involve risks and high costs.
VIZZ emerges as a daily, non-invasive alternative that could be especially appealing to active people seeking freedom from glasses during events, meetings, or travel.
Impact on the Market and Possibility of Expansion
Although initially restricted to the United States, experts believe that the eye drop that corrects vision may reach other countries in the coming years, depending on the approval of local regulatory agencies.
If the product maintains its efficacy and safety in real users, it could create a multibillion-dollar impact in the optical sector, challenging everything from lens manufacturers to refractive surgery clinics.
What Is Presbyopia and Why Is Everyone Susceptible
Presbyopia is a natural process of ocular aging that typically begins around age 40. It occurs because the lens — the natural lens of the eye — loses elasticity, making it difficult to focus on nearby objects.
This is not a disease, but an inevitable condition. Until now, the most common solution was the use of reading glasses. VIZZ changes this logic by offering a temporary, yet functional treatment that dispenses with corrective lenses during the period of action.
-
-
-
4 people reacted to this.